Mirae Asset Global Investments Co. Ltd. Sells 10,661 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 13.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 71,088 shares of the company’s stock after selling 10,661 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.16% of Omnicell worth $9,205,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of OMCL. Goldman Sachs Group Inc. increased its position in Omnicell by 255.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 617,199 shares of the company’s stock worth $111,367,000 after purchasing an additional 443,378 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Omnicell by 12.5% in the first quarter. Conestoga Capital Advisors LLC now owns 1,691,338 shares of the company’s stock worth $219,011,000 after purchasing an additional 188,112 shares during the last quarter. Clearbridge Investments LLC increased its position in Omnicell by 8.9% in the first quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company’s stock worth $147,187,000 after purchasing an additional 92,567 shares during the last quarter. Global Alpha Capital Management Ltd. increased its position in Omnicell by 49.2% in the first quarter. Global Alpha Capital Management Ltd. now owns 199,610 shares of the company’s stock worth $25,847,000 after purchasing an additional 65,830 shares during the last quarter. Finally, Berry Street Capital Management LLP bought a new stake in Omnicell in the first quarter worth $8,093,000.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OMCL. Piper Sandler cut their price objective on shares of Omnicell from $162.00 to $150.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. BTIG Research cut their price objective on shares of Omnicell from $190.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, July 27th. KeyCorp began coverage on shares of Omnicell in a research report on Thursday, September 15th. They set an “overweight” rating and a $130.00 price objective on the stock. SVB Leerink began coverage on shares of Omnicell in a research report on Friday, July 15th. They set a “market perform” rating and a $124.00 price objective on the stock. Finally, Bank of America began coverage on shares of Omnicell in a research report on Friday, September 9th. They set a “buy” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Omnicell has a consensus rating of “Moderate Buy” and a consensus target price of $151.71.

Omnicell Stock Down 3.3 %

Shares of OMCL opened at $89.92 on Wednesday. The firm has a market capitalization of $3.98 billion, a P/E ratio of 71.37, a P/E/G ratio of 2.65 and a beta of 1.06. Omnicell, Inc. has a 12-month low of $88.44 and a 12-month high of $187.29. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average price of $106.32 and a 200-day moving average price of $114.53.

Omnicell (NASDAQ:OMCLGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.01). Omnicell had a net margin of 4.82% and a return on equity of 10.37%. The company had revenue of $331.39 million for the quarter, compared to analysts’ expectations of $339.45 million. During the same period in the prior year, the firm posted $0.71 earnings per share. The firm’s revenue for the quarter was up 21.5% compared to the same quarter last year. Equities research analysts expect that Omnicell, Inc. will post 2.7 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Peter J. Kuipers sold 15,500 shares of the company’s stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $108.29, for a total value of $1,678,495.00. Following the completion of the sale, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at $6,640,992.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Peter J. Kuipers sold 15,500 shares of the company’s stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $108.29, for a total value of $1,678,495.00. Following the completion of the sale, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at $6,640,992.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Peter J. Kuipers sold 11,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the completion of the sale, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at $6,496,263.18. The disclosure for this sale can be found here. Insiders sold a total of 39,500 shares of company stock valued at $4,287,245 over the last three months. 2.76% of the stock is owned by company insiders.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Stories

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.